This article is more than 5 years old. Information may no longer be current.

Ophthotech acquires development rights for two potential AMD drugs

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PRINCETON, N.J. — Ophthotech Corp. has been granted development rights to Archemix Corp.'s proprietary C5-targeting aptamers and Eyetech's anti-platelet derived growth factor aptamer program, the company announced.

Archemix granted Ophthotech exclusive worldwide rights to all ophthalmic uses of its aptamers that target the C5 component of the complement cascade in wet and dry forms of age-related macular degeneration, according to an Ophthotech press release.

Additionally, Eyetech, a subsidiary of OSI Pharmaceuticals, has transferred all rights to its anti-PDGF aptamer program to Ophthotech, including the compound E10030. In pre-clinical studies, E10030 showed the potential for causing the regression of neovascularization when used in combination with a VEGF inhibitor, according to the release.

Ophthotech has also raised $36 million in Series A financing, which it will use to support development of both compounds, the release said.